Whittier Trust Co. Sells 10,337 Shares of Abbott Laboratories $ABT

Whittier Trust Co. decreased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 6.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 161,526 shares of the healthcare product maker’s stock after selling 10,337 shares during the quarter. Whittier Trust Co.’s holdings in Abbott Laboratories were worth $16,088,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ABT. Bank of America Corp DE bought a new stake in Abbott Laboratories during the 2nd quarter worth approximately $1,603,607,000. Legal & General Group Plc bought a new position in shares of Abbott Laboratories in the second quarter valued at approximately $1,082,524,000. Flossbach Von Storch SE bought a new position in shares of Abbott Laboratories in the second quarter valued at approximately $902,938,000. Jupiter Topco LLC purchased a new position in shares of Abbott Laboratories during the second quarter valued at approximately $732,788,000. Finally, BlackRock Inc. boosted its position in shares of Abbott Laboratories by 4.6% during the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock valued at $13,843,610,000 after buying an additional 6,769,518 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the sale, the executive vice president owned 100,791 shares of the company’s stock, valued at approximately $11,691,756. The trade was a 3.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories News Summary

These are some of the ABT news items that stood out recently:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
  • Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
  • Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Citigroup decreased their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating for the company in a report on Thursday, October 22nd. BTIG Research dropped their price objective on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Argus downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Barclays initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price for the company. Finally, Wells Fargo & Company upped their target price on shares of Abbott Laboratories from $112.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $119.04.

Get Our Latest Stock Report on Abbott Laboratories

Abbott Laboratories Stock Down 0.9%

Shares of NYSE:ABT opened at $102.96 on Friday. The company has a market capitalization of $178.32 billion, a PE ratio of 38.42, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.45 and a quick ratio of 1.00. The business has a fifty day moving average price of $103.91 and a two-hundred day moving average price of $101.66. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $129.85.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.42. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business’s revenue was up 14.5% compared to the same quarter last year. During the same period last year, the firm posted $1.30 EPS. Analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.